Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Milatuzumab

EU orphan designation number: EU/3/08/602   
Active ingredient: Milatuzumab
Indication: Treatment of chronic lymphocytic leukaemia
Sponsor: Immunomedics GmbH
Otto-Röhm-Straße 69, D-64293 Darmstadt, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/01/2009 Centralised Orphan - Designation EMEA/OD/058/08 (2009)390 of 19/01/2009